American Healthcare initiates quarterly dividend of $0.25 a share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2024
0mins
Source: SeekingAlpha
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on AHR
Wall Street analysts forecast AHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AHR is 55.36 USD with a low forecast of 47.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 46.330
Low
47.00
Averages
55.36
High
60.00
Current: 46.330
Low
47.00
Averages
55.36
High
60.00
About AHR
American Healthcare REIT, Inc. is a real estate investment trust that acquires, owns and operates a diversified portfolio of clinical healthcare real estate, focusing primarily on senior housing, skilled nursing facilities, outpatient medical (OM) buildings and other healthcare-related facilities across the United States, the United Kingdom and the Isle of Man. It owns and operates its integrated senior health campuses and senior housing operating properties (SHOP). Its segments include integrated senior health campuses, OM, SHOP and triple-net leased properties. Its OM buildings are leased to multiple tenants under separate leases. Its integrated senior health campuses each provide a range of independent living, assisted living, memory care, skilled nursing services and ancillary businesses. Its triple-net leased properties segment includes senior housing, skilled nursing facilities and hospitals. Its SHOP segment includes senior housing providing assisted living care, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Rating Changes Overview: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Impact: The changes in analysts' ratings could influence investor decisions, particularly for those considering buying SBET stock, highlighting the importance of understanding these ratings.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, offering a comprehensive market perspective.
- Investment Advice: While Benzinga provides market data, it does not offer specific investment advice, leaving investors to assess risks and rewards independently.
Continue Reading
S&P MidCap and SmallCap Index Changes Announced
- MidCap Addition: TTM Technologies (TTMI) will be added to the S&P MidCap 400 on January 30, 2026, highlighting its recognition in the information technology sector, which is expected to enhance its market liquidity and investor interest.
- MidCap Deletion: Civitas Resources (CIVI) will be removed from the S&P MidCap 400 on the same date, which may impact its stock performance and market confidence, reflecting its relative weakness in the energy sector.
- SmallCap Addition: Amneal Pharmaceuticals (AMRX) will join the S&P SmallCap 600 on January 30, 2026, strengthening its market position in the healthcare industry and likely attracting more investor attention.
- SmallCap Deletion: TTM Technologies (TTMI) will also be removed from the S&P SmallCap 600 on the same date, indicating its poor performance in the small-cap market, which may lead investors to reassess its investment value.
Continue Reading